Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Botanix Pharmaceuticals Limited ( (AU:BOT) ) has shared an announcement.
Botanix Pharmaceuticals Limited announced the quotation of 200,000 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of September 3, 2025. This move is part of the company’s strategy to enhance its market presence and provide additional value to its stakeholders by expanding its financial base and operational capabilities.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$0.27 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development and commercialization of dermatology and antimicrobial products. The company aims to address unmet needs in skin diseases and infections through innovative therapeutic solutions.
Average Trading Volume: 15,090,331
Technical Sentiment Signal: Sell
Current Market Cap: A$284.4M
See more data about BOT stock on TipRanks’ Stock Analysis page.